Advertisement

Topics

Anti-VEGF protocol with guided laser reduces treatment burden but adds no visual acuity benefit

09:30 EST 13 Nov 2017 | Healio

David M. brown
NEW ORLEANS — At 2 years, the TREX-DME trial demonstrated that adjuvant focal laser treatment provided no statistically significant anatomic benefit in patients treated with Lucentis, while a treat-and-extend protocol, with laser or without, did reduce treatment burden, David M. Brown, MD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.
The objective of the trial was to compare monthly Lucentis (ranibizumab, Genentech) vs. treat-and-extend ranibizumab vs. guided laser plus treat-and-extend ranibizumab in patients with diabetic

Original Article: Anti-VEGF protocol with guided laser reduces treatment burden but adds no visual acuity benefit

NEXT ARTICLE

More From BioPortfolio on "Anti-VEGF protocol with guided laser reduces treatment burden but adds no visual acuity benefit"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...